Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2011 Amrita Ghaswalla	Changing the Dialogue No industry leader is more closely associated with the goal of seeding the globe with low-cost generics than Mumbai-based Cipla Chairman Y.K. Hamied.
Wired December 2006 Erika Check	The Treasure of Mumbai In the pharmaceutical industry, Indian drugmaker Cipla is a pirate operation. To the developing world, it's a vital medicine chest. And now its cheap pills are coming to a pharmacy near you.
BusinessWeek April 18, 2005 Manjeet Kripalani	India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India.
Chemistry World March 20, 2012 Rajesh Parishwad	India Green Lights Production of Patented Cancer Drug For the first time India has invoked a 'compulsory license' clause to cut the cost of a patented anti-cancer drug by allowing another company to manufacture the therapy.
Chemistry World July 25, 2012	Pharma Industry May Suffer as India Looks to Generics India plans to provide free generic drugs to half its population.
Chemistry World January 21, 2013 Andy Extance	India pushes for emergency drug licenses The Indian government is preparing to grant compulsory licenses allowing three patented cancer drugs to be produced in the country and sold at reduced rates without permission from the patent owners.
Salon.com June 1, 2001 Daryl Lindsey	The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical?
Chemistry World July 11, 2012 Ling Wang	China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances.
Chemistry World October 17, 2014 Dinsa Sachan	Indian manufacturers hit back over quality claims The Indian pharmaceutical industry has asked its government to sue authors of a study published by the US National Bureau of Economic Research in early September.
Pharmaceutical Executive April 1, 2014 Subramanian et al.	"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India.
Chemistry World April 8, 2013 Sarah Houlton	India rejects Novartis patent appeal India's Supreme Court has denied Novartis' appeal against the decision to refuse patent protection for its anticancer drug Glivec (imatinib mesylate).
Chemistry World September 17, 2010 Andrew Turley	Free trade could throttle generics from India International agreements on intellectual property threaten the flow of generic HIV drugs from India to developing countries, according to a new report.
Chemistry World August 6, 2007 Victoria Gill	Novartis Loses Indian Patent Law Case Swiss drug firm Novartis has lost its legal case against the Indian government, who it had accused of 'unconstitutional' patent law practices. The ruling sets an important precedent that will cheer the flourishing generics market in the country.
Chemistry World September 23, 2014 Phillip Broadwith	Gilead licenses generic hepatitis C drug in India Gilead has granted licenses to seven generic drugmakers to produce its blockbuster hepatitis C drug Sovaldi (sofosbuvir) in India and 90 other developing nations.
Chemistry World September 3, 2014 Rajesh Parishwad	Piramal exits drug discovery in India India's Piramal Enterprises is exiting its early-stage drug discovery research and focusing on late clinical development, along with its core areas such as generics and contract research services.
BusinessWeek February 27, 2006 Einhorn & Kripalani	In India, Selling Generics Used To Be So Easy Suddenly, Indian drugmakers Dr. Reddy's and Ranbaxy have a host of copycat rivals.
Chemistry World August 24, 2009 Sarah Houlton	Indian court dismisses Bayer's patent law case Bayer has failed in its attempt to stop Indian regulators giving marketing authorization to a generic version of its kidney cancer drug Nexavar (sorafenib), despite its 20 year patent having only been granted last year.
BusinessWeek January 12, 2004 Manjeet Kripalani	India: Big Pharma's New Promised Land? Drugmakers are heeding the siren call of its well-trained, cheap chemists.
Chemistry World June 13, 2008 Sarah Houlton	Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses.
Chemistry World September 10, 2014 Emma Stoye	Cipla targets asthma market with Advair copy Indian pharma company Cipla has begun selling a generic version of GlaxoSmithKline's combination asthma treatment Advair (fluticasone/salmeterol) in Germany and Sweden.
Pharmaceutical Executive September 1, 2013 William Looney	High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets.
Pharmaceutical Executive April 1, 2012	Leading from the South India's most prominent scientist sets a new agenda for pharma in emerging markets.
Pharmaceutical Executive October 1, 2010	Taking a Less-Generic Route to Generics A leading pharmaceutical industry player speaks out on what is fueling success in the sector.
Pharmaceutical Executive July 3, 2007	Thought Leader: Connected Markets, Rob Dhoble It used to be that pharma companies had one marketing strategy for the US and other developed nations, a second strategy for emerging countries, and a third, mostly focused around access, for the developing world. But in a global environment, that doesn't work.
The Motley Fool March 28, 2005 Brian Gorman	A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.
Salon.com August 22, 2001 Michael McColly	Whisper of death Poverty, a rigid class system and conservative Hindu values are quickly turning India into the next South Africa in the global AIDS pandemic...
BusinessWeek October 10, 2005 Manjeet Kripalani	India: A Quiet Shopping Spree So far, foreign companies being bought by Indian players are small - but that's likely to change
Reason June 2006 Samuel R. Staley	The Rise and Fall of Indian Socialism Why India embraced economic reform.
Chemistry World February 12, 2015 S Umapathy	Indian science at the crossroads How should Indian scientific research evolve?
Chemistry World February 3, 2015 Sanjay Kumar	India's chemistry challenges While India is yet to catch up with the global cutting edge technologies, some of its interventions have made global headlines.
Investment Advisor October 2010 Savita Iyer-Ahrestani	Jewels in the Crown As wealth mushrooms in India, the need for Western-style advice grows
Chemistry World March 6, 2015 Sanjay Kumar	Scientists left unimpressed by Indian budget The Indian government's 'big-bang' budget has left the country's science community sorely disappointed.
BusinessWeek March 29, 2004 Manjeet Kripalani	Ban Outsourcing? Bad Idea Such legislation in the U.S. could derail India's moves to open its economy
The Motley Fool October 15, 2010 Tim Hanson	A Huge Opportunity in Retail India could be the next portal for big retailers.
BusinessWeek February 16, 2004 Gary S. Becker	What India Can Do To Catch Up With China India began to turn around its economy a little more than a decade ago -- and with further free-market reforms, it can give China a run for being the most dynamic big developing country.
CIO November 2, 2011 John Ribeiro	India Exempts Its Outsourcers from New Privacy Rules India's outsourcing industry breathes a sigh of relief as the government exempts it from strict new data protection rules.
Chemistry World December 18, 2015 Ned Stafford	India maintains scientific edge despite static funding Researchers in India are increasingly authoring articles published in 'high-quality scientific publications' despite continued stagnation in Indian government spending for research, according to a new Nature Index analytics report.
The Motley Fool September 9, 2010 Andrew Bond	Invest in India for Fast Growth Consider these strong Indian companies for your portfolio.
U.S. Banker November 2009 Joseph Rosta	India Needs More Banks India offers an expanding middle class and a seriously under-banked population. Western banks should be paying attention.
InternetNews December 6, 2005 Colin C. Haley	Microsoft Plans 30 New R&D Centers Microsoft Chairman Bill Gates kicked off a four-day India trip by outlining a plan to build 30 new innovation centers around the world, including one in the tech-heavy Indian city of Bangalore.
Chemistry World October 8, 2010 Akshat Rathi	India calls for ambitious increase in science funding The Scientific Advisory Council to the Prime Minister of India has advised the government to increase its science funding from less than 1 per cent of GDP to up to 2.5 per cent by 2020.
Global Services July 7, 2007 Shyamanuja Das	The Acquisitive Indian Indian tech and outsourcing companies seem to be on a buying spree. In the last few months, every Indian company worth its name has either acquired another or has set aside a few million to do so in the near future.
The Motley Fool December 9, 2009	Read This Before You Buy India A local expert shares the secret to investing in the fast-growing sectors of the country.
IndustryWeek December 1, 2008 Adrienne Selko	Doing Business in 21st Century India: How to Profit Today in Tomorrow's Most Exciting Market Advice on how to succeed in India.
CFO June 1, 2004 Justin Wood	The View from the East India's upstart IT-services firms face their own challenges from their giant rivals in the West.
The Motley Fool December 9, 2010 Tim Hanson	Still the Biggest Investment Opportunity in India Why India's power sector remains worthy.
The Motley Fool March 10, 2011 Isac Simon	India Prepared for $1 Trillion in Infrastructure Spending The Indian budget finally organizes a framework for foreign investments.
The Motley Fool June 9, 2006 John Finneran	IBM: "I" Stands for India IBM will invest $6 billion in India -- but why?
IndustryWeek August 1, 2006 Jonathan Katz	Auto Parts: The New Kid In Town U.S. auto-components manufacturers take note: India wants your customers.
The Motley Fool August 30, 2006 Brian Gorman	An Integrated India Strategy From EADS Plans to outspend Boeing in India could mean more commercial and defense business in the country. Investors, take note.